Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial of Certepetide + SoC chemo combo in Metastatic Pancreatic Cancer announced July 1, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
Ph 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda in 1L Treatment for Advanced or Metastatic MCC initiated July 1, 2025
Positive pivotal data announced for zidesamtinib in TKI pre-treated patients with ROS1-positive NSCLC from ARROS-1 Ph 1/2 trial July 1, 2025
FDA approves label updates for Breyanzi and Abecma to reduce certain patient monitoring requirements and removes the Risk Evaluation and Mitigation Strategy (REMS) programs July 1, 2025
Sanofi to advance Kymera’s next-gen oral IRAK4 degrader KT-485 into clinical testing and will not advance KT-474 July 1, 2025
Ph 3 FORTITUDE-101 of 1L bemarituzumab plus chemotherapy (mFOLFOX6) in gastric cancer patients met primary endpoint of OS July 1, 2025
FDA grants Priority Review to Supplemental NDA for Revuforj® (revumenib) in R/R mNPM1 AML; PDUFA action date Oct 2025 July 1, 2025
Hummingbird Bioscience Licenses HMBD-002, Ph 2-Ready Anti-VISTA Monoclonal Antibody, to Percheron Therapeutics July 1, 2025
Revolution Medicines and Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for RAS-Addicted Cancers July 1, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders July 1, 2025
Xcell Biosciences and Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies July 1, 2025
First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab July 1, 2025
First Patient Dosed in DENALI-1 Ph 1/2 Clinical Study of A2B395 CAR T Cell Therapy for Patients with EGFR-expressing Solid Tumors July 1, 2025
First patient dosed in Ph 1/2 trial of TNG462 and daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer July 1, 2025
Second patient dosed in Ph 2 trial protocol of stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer July 1, 2025
CDR609 Announced as New T-Cell Engager Clinical Candidate Targeting LGR5 in Solid Tumors July 1, 2025
Results from Ph 1 FRAME Study of Avutometinib + Defactinib combo in Solid Tumors, including Low-Grade Serious Ovarian Cancer, published in Nature Medicine July 1, 2025
Early-Stage Clinical Data and Anti-Proliferative Results Reported for APR-1051 in HPV+ HNSCC July 1, 2025
Statistically Significantly Positive 1-Year EFS, OS, and Safety Clinical Data Updates for OST-HER2 in osteosarcoma patients July 1, 2025
